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OBJECTIVE: To estimate the incidence and prevalence of thromboangiitis obliterans in Taiwan in the period
spanning from 2002 to 2011.
METHODS: We identified all incident and prevalent cases with a diagnosis of thromboangiitis obliterans
(International Classification of Diseases, Ninth Revision code 443.1) in the period spanning from 2002 to 2011
using Taiwan’s National Health Insurance Research Database. We calculated the age- and sex-specific incidence
and prevalence rates of thromboangiitis obliterans during the study period.
RESULTS: From 2002 to 2011, 158 patients were diagnosed with thromboangiitis obliterans; of these, 76% were
men. Most (63%) of the patients wereo50 years old when they were first diagnosed. After reaching 20 years of
age, the incidence rate increased with age and peaked among those aged X60 years. The average incidence
rate of thromboangiitis obliterans during the 2002–2011 period was 0.068 per 105 years. The incidence of
thromboangiitis obliterans decreased with time, from 0.10 per 105 years in 2002 to 0.04 per 105 years in 2011.
The prevalence increased from 0.26  10 5 in 2002 to 0.65  10 5 in 2011.
CONCLUSION: This is the first epidemiologic study of thromboangiitis obliterans using claims data from a
general population in Taiwan. This nationwide, population-based study found that the incidence and
prevalence of thromboangiitis obliterans in Taiwan in the 2002–2011 period were lower than those in other
countries before 2000. This study also revealed a trend of decreasing incidence with simultaneous increasing
prevalence of thromboangiitis obliterans in Taiwan from 2002 to 2011.
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’ INTRODUCTION
Thromboangiitis obliterans (TAO) is a nonatherosclerotic,
segmental, chronic inflammatory disease. TAO mainly affects
the small and medium-sized arteries, veins and nerves of the
arms and legs (1). Affected patients usually suffer from
ischemic pain, ulcers, or gangrenous patches in the distal
limbs (2). If not treated early and adequately, TAO can result
in limb amputation (2). There are several diagnostic criteria for
TAO. The diagnostic criteria proposed by Shionoya (3,4) in
1983 comprise an onset before the age of 50 years, a smoking
history, the presence of infrapopliteal arterial occlusions, either
upper limb involvement or phlebitis migrans and the lack of
atherosclerotic risk factors other than smoking. In 1993, Mills
& Porter (5) proposed another set of diagnostic criteria for
TAO, consisting of major and minor criteria. In 1996, Papa et
al. (6) suggested a point system for TAO diagnosis. In 2000,
Olin JW (1) recommended another set of criteria that included
an onset age o45 years with a history of current/recent
smoking, the existence of distal limb ischemia proven by
noninvasive vascular imaging examinations, the absence of a
proximal source of emboli and the presence of coherent
arteriographic findings in symptomatic and noninvolved
extremities. Von Winiwarter initially defined TAO in 1879
(7), but its etiology and pathogenesis has not been elucidated
to date (8). Genetic and environmental factors, particularly
tobacco use, have been proposed as risk factors for TAO (9).
Although little is known about the exact pathogenesis of TAO
and its association with smoking (10), the withdrawal of
tobacco use usually halts disease progression and remains the
most important treatment to date (10). Anti-angiogenicDOI: 10.6061/clinics/2016(07)08
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activity is present in the sera of TAO patients (11). However,
the efficacy of therapeutic angiogenesis has not been proven in
relevant controlled trials.
TAO typically occurs in young male smokers of low
socioeconomic status, with a mean age of onset of between
35 and 50 years (4,12,13). Prior epidemiologic studies have
shown that TAO is more prevalent in the Middle East and
the Far East than in North America and Western Europe, and
its prevalence has decreased over time in developed
countries (14-16). Most previous epidemiologic studies were
conducted using hospital-based data (14,15,17). Although
Hida & Ohta (18) reported the number of incident and
prevalent cases of TAO in Japan using a nationwide registry
database in 2009, they did not calculate the incidence
rate and prevalence of the condition. In all patients with
peripheral arterial disease, the prevalence of TAO has been
reported as 0.5-5.6% in Western Europe, 15-66% in Korean
and Japan, and 45-63% in India (19). Few epidemiologic
studies have reported the incidence and prevalence of TAO
after 2000 (20). Additionally, a paucity of epidemiologic data
for TAO has been collected from the general population (21).
Furthermore, the incidence and prevalence of TAO in Taiwan
have never been studied. We previously conducted a
nationwide, population-based epidemiologic study of com-
mon variable immunodeficiency using the Taiwanese
National Health Insurance Research Database (NHIRD)
(20). The aim of the current study was to investigate the
prevalence and incidence of TAO during the 2002–2011
period in Taiwan using the NHIRD.
’ MATERIALS AND METHODS
Study design
The present study utilized a nationwide, retrospective,
cohort study design.
Data source
The Taiwan government launched a compulsory, single-
payer National Health Insurance (NHI) program on March 1,
1995. The NHI program covered over 98% of Taiwan’s
population. The National Health Research Institute handled
the NHIRD and released encoded NHI-related administra-
tive data, including outpatient, inpatient and enrollment
files, for study purposes. Although comprehensive informa-
tion such as medical services and drug prescriptions were
included in the NHIRD, some personal information such as
tobacco and alcohol use was not available. This study used
multiple NHIRD datasets, including inpatient and ambula-
tory claims, enrollment and NHI catastrophic illness files
from the 1997–2011 period.
The 1997–2011 period inpatient and ambulatory records
offer data regarding date of visit/hospitalization, diagnosis,
treatment and medical expenditures. Enrollment files deliv-
ered enrollment information and demographic data. The
Bureau of NHI (BNHI) registered patients with catastrophic
or major diseases, including some rheumatic illnesses such as
rheumatoid arthritis and TAO. Their enrollment, ambulatory
and inpatient claims were distributed as NHI catastrophic
illness files. The BNHI issues a catastrophic illness certificate
to those who have a catastrophic illness diagnosis, which is
validated by at least two specialists after a careful review of a
patient’s original medical records. Those who are issued a
catastrophic illness certificate are excused from copayment.
Study samples
Using the Taiwanese NHIRD, this study identified all TAO
patients (ICD9-CM 443.1) who received a catastrophic illness
certificate during the 2002–2011 period to calculate the
prevalence and mortality rates of TAO. All of the deaths
that occurred in patients with TAO, regardless of the cause,
were used to calculate the mortality rate (i.e., all-cause
mortality). To identify the incident cases, we excluded
those who had received a TAO diagnosis before 2002. Age
of onset was calculated based on the date of application for a
catastrophic illness certificate.
Statistical analysis
We calculated the annual incidence, prevalence and
mortality rates of TAO during the 2002–2011 period. We
also calculated the age- and gender-specific incidence and
prevalence of TAO during this period. All statistical analyses
were performed using SAS statistical software, version 9.2
(SAS Institute, Cary, NC).
Ethics
The Ethics Committee for Clinical Research of Taichung
Veterans General Hospital approved the study protocol.
Because information about personal identification was
detached from the dataset before analysis, written informed
consent was not attained.
’ RESULTS
Table 1 and Figure 1 show the age-specific incidence rates
of TAO in Taiwan. Between 2002 and 2011, 158 patients were
newly diagnosed with TAO; of these, 76% were men. Two
men and two women who were under 20 years in age were
diagnosed with TAO. The incidence rate increased among
individuals over 20 years in age and peaked at age
X60 years. Most (63%) of the patients were diagnosed
Table 1 - Age-specific incidence of thromboangiitis obliterans in Taiwan from 2002 to 2011.
Case number Person-years Incidence rate (per 105 years)
Age group F M T F M T F M T
0–9 1 2 3 19050837 20763899 39814736 0.01 0.01 0.01
10–19 1 0 1 16112069 17223717 33335786 0.01 0.00 0.00
20–29 7 20 27 20335969 19005493 39341462 0.03 0.11 0.07
30–39 1 30 31 19137215 19243068 38380283 0.01 0.16 0.08
40–49 8 29 37 17444626 17434089 34878714 0.05 0.17 0.11
50–59 5 17 22 10321223 10007057 20328281 0.05 0.17 0.11
X60 15 22 37 12027557 11781867 23809424 0.12 0.19 0.16
F, Female; M, Male; T, Total.
Thromboangiitis obliterans: ICD-9 code 443.1 with catastrophic illness certificate.
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before reaching 50 years in age, while 23% of the patients
were diagnosed after age 60.
As shown in Table 2, the prevalence of TAO increased
with time, from 0.26  10-5 in 2002 to 0.65  10-5 in 2011. On
the contrary, there was a trend toward a decreasing incidence
of TAO from 2002 to 2011 among both men and women.
The incidence rate declined from 0.10 per 105 years in 2002 to
0.04 per 105 years in 2011. The annual average mortality rate
ranged from 0% to 6.5%.
’ DISCUSSION
To the best of our knowledge, this study is the first
population-based epidemiologic study of TAO using claims
data from Taiwan. We found a trend of decreasing incidence
of TAO, consistent with findings from previous studies that
have investigated the epidemiology of TAO in other regions.
For example, at Nagoya University Hospital in Japan, 46 new
patients with TAO were hospitalized between 1985 and 1989,
whereas only 12 new patients were hospitalized between
1990 and 1996 (15). The decreasing incidence rate from 2002
to 2011 in Taiwan may be attributed to improvements in
socioeconomic status as well as the decreased smoking rate
resulting from the implementation of smoke-free policies
(15, 16). From 2002 to 2011 in Taiwan, the gross domestic
product (GDP) per capita increased from 13,750 United
States dollars (USD) to 20,939 USD, and the total national
income (GNI) per capita increased from 14,062 USD to 21,507
USD (22). Additionally, the overall reported smoking rate
decreased from 24.2% in 2004 to 16.9% in 2011 (23). Prior
studies have also found an association between chronic
anaerobic periodontal infection and development of TAO
(24,25). We speculate that the decreasing incidence of TAO
through the study period is associated with better
oral hygiene. However, epidemiologic data regarding the
prevalence of periodontal disease in Taiwan are not available
to support this hypothesis.
The prevalence of TAO in Taiwan increased from
0.26/100,000 in 2002 to 0.65/100,000 in 2011. The prevalence
of TAO in Taiwan was much lower than that estimated for
the general population in North America during the 1960s
through 1980s (8-13/100,000) (14,26,27). It was also lower
Figure 1 - Age-specific incidence of thromboangiitis obliterans in Taiwan from 2002 to 2011.
Table 2 - Incidence and prevalence of thromboangiitis obliterans in Taiwan from 2002 to 2011.
Total population (millions) Incidence case Prevalence case Death case Incidence (per 105 years) Prevalence (105)
Year F M T F M T F M T F M T F M T F M T
2002 11.38 11.62 23.01 12 11 23 23 36 59 2 1 3 0.11 0.09 0.10 0.20 0.31 0.26
2003 11.48 11.34 22.81 1 21 22 22 56 78 1 2 3 0.01 0.19 0.10 0.19 0.49 0.34
2004 11.38 11.18 22.56 4 8 12 25 62 87 3 2 5 0.04 0.07 0.05 0.22 0.55 0.39
2005 11.71 11.48 23.18 3 14 17 25 74 99 3 3 6 0.03 0.12 0.07 0.21 0.64 0.43
2006 11.79 11.54 23.33 6 8 14 28 79 107 2 4 6 0.05 0.07 0.06 0.24 0.68 0.46
2007 11.86 11.57 23.44 5 17 22 31 92 123 4 4 8 0.04 0.15 0.09 0.26 0.79 0.52
2008 11.93 11.62 23.55 2 13 15 29 101 130 3 1 4 0.02 0.11 0.06 0.24 0.87 0.55
2009 11.97 11.59 23.56 2 9 11 28 109 137 1 4 5 0.02 0.08 0.05 0.23 0.94 0.58
2010 12.01 11.60 23.61 2 11 13 29 116 145 0 0 0 0.02 0.09 0.06 0.24 1.00 0.61
2011 12.05 11.62 23.67 1 8 9 30 124 154 2 3 5 0.01 0.07 0.04 0.25 1.07 0.65
F, Female; M, Male; T, Total.
Thromboangiitis obliterans: ICD-9 code 443.1 with catastrophic illness certificate.
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than that in Japan in 1985 (5/100,000) (28). However, no
previous studies have reported the prevalence of TAO in the
general population during the 2002-2011 period. Variations
in diagnostic criteria, study period and race may partly
explain the inconsistencies in the prevalence data.
Several studies have shown an increasing prevalence of
TAO in women, which is considered to result from increases
in smoking practices among women (12,29,30). In our study,
the prevalence and incidence of TAO among women in
Taiwan remained low throughout the study period. This may
be explained by the fact that the smoking rate among women
aged over 18 years remained low in Taiwan, being reported
as 5.3% in 2002 and 4.3% in 2011 (23). Similarly, a low
prevalence of TAO among women has also been found in
studies conducted in Japan (28) and Hong Kong (31).
Disease onset before the age of 50 years was included in
the commonly used Shionoya classification criteria for TAO
(4). In our study, we found that nearly one quarter of the
patients were diagnosed with TAO after reaching 60 years of
age. One possible explanation for this finding is that
the diagnosis of TAO was delayed by over a decade for
some of the patients, which may have further caused a delay
in discontinuing tobacco use and could be associated with a
poorer outcome (32).
It is worth mentioning that we identified 3 patients who
developed TAO before reaching 10 years of age in this study.
To the best of our knowledge, only a few case reports in the
literature have described the development of TAO in
children (33-36).
Therefore, we cannot exclude the possibility that these
cases were misdiagnosed or miscoded in the NHIRD.
A main strength of this population-based study is its
minimized selection bias. However, the study also has some
limitations that should be addressed. First, TAO diagnosis
was based on claims data; therefore, its accuracy may be of
concern. However, the enrollment of those who were issued
a TAO catastrophic certificate likely increased the accuracy of
diagnosis. Second, because listing in the catastrophic illness
registry is not mandatory, some TAO patients who were
unwilling to apply for a catastrophic illness certificate may
have been neglected in our analysis, leading to under-
estimation of the incidence and prevalence of TAO. Third,
because the NHIRD lacked information regarding cause of
death, we were unable to analyze the cause of TAO-
associated mortality in Taiwan. Finally, the exact age of
disease onset was not accessible from the NHIRD. Some
patients may not have visited doctors immediately after
symptoms occurred, whereas others may have initially been
diagnosed with other diseases. Therefore, we may have
overestimated the age of onset in our analysis.
The current study is the first population-based study to
describe the epidemiology of TAO in Taiwan using the
NHIRD. The incidence and prevalence of TAO in Taiwan
during the period spanning from 2002 to 2011 were lower
than those in other countries before 2000. This study also
revealed a trend of decreasing incidence rate simultaneous
with increasing prevalence of TAO from 2002 to 2011.
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